IP Library Granted Patent US 8,471,024
Granted Patent B2
US 8,471,024 · App. 12/919,156 · Granted Jun 25, 2013

Tetrahydrofuropyridones

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,471,024
App. No.
12/919,156
Granted
Jun 25, 2013
Kind
B2
Abstract

The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Claims (92)

1. A compound of formula I and pharmaceutically acceptable salts thereof

wherein

one of X, Y, or W is O and the other two moieties are —CR 4 R 5 and —CR 6 R 7 ;

R 8 is selected from hydrogen, C 1-6 alkyl, optionally substituted with a hydroxy, —SH, —NH 2 or —CO 2 H, and C 3-6 cycloalkyl optionally substituted with a hydroxy, —SH, —NH 2 or —CO 2 H;

n is 0, 1, or 2;

R 1 is selected from

—C 1-10 alkyl,

—C 2-10 alkenyl,

—C 5-10 cycloalkenyl,

—C 2-10 alkynyl,

—C 0-10 alkylaryl,

—C 0-10 alkylheterocyclyl,

—C 0-10 alkyl-C 0-10 cycloalkyl, and

perfluoroC 1-6 alkyl;

wherein in R 1 said alkyl, alkenyl, alkynyl, cycloalkenyl, aryl, heterocycloalkyl, heterocyclyl, and cycloalkyl are each optionally substituted with one or more R 9 substituents;

R 2 and R 3 are independently selected from hydrogen, phenyl, heterocyclyl, and —C 1-10 alkyl,

wherein C 1-10 alkyl is unsubstituted or substituted with one or more fluorine atoms, and phenyl is unsubstituted or substituted with or more substituents selected from fluoro, chloro, hydroxyl,

C 1-10 alkyl, and —OC 1-10 alkyl;

R 4 , R 5 , R 6 , and R 7 are independently selected from hydrogen, cyano, oxo, —C 1 -C 10 alkyl, —C 2-10 alkenyl, —C 3-10 cycloalkyl, —(C 1-10 alkyl)aryl, (C 0-10 alkyl)heterocyclyl, —C 5-10 cycloalkenyl, —C 2-10 alkynyl, —SO n (C 1-10 alkyl) and —SO n aryl wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl are optionally substituted by one or more substituents R 9 , and

optionally one set of substituents, R 4 and R 5 , or R 6 and R 7 , are linked together to form a ring of 5 to 8 atoms optionally substituted with one or more substituents R 9 , where said ring is partially or fully unsaturated having 0, 1 or 2 heteroatoms independently selected from —NR 6 —, —O— and —S(O) n —;

R 9 is selected from halogen, hydroxy, oxo, cyano, aryl, heterocyclyl, —C 1-6 alkyl, O(C═O) 0-1 C 1-6 alkyl, —C 1-6 alkoxy, —O (0-1) (C 1-10 )perfluoroalkyl, aryloxy, heterocyclyloxy, —CO 2 R a , —NR b R c , —CONR b R c , —OCO 2 R a , —OCONR b R c , —NR d CO 2 R a , —NR d CONR b R c , —SC 0-6 alkyl and —S(O) n R d , wherein said aryl, heterocyclyl, alkoxy, aryloxy, heterocyclyloxy are optionally substituted by one or more substituents R 10 ;

R 10 is selected from hydroxy, aryl, heterocyclyl, halogen, —C 1-6 alkyl, C 1-6 alkoxy, halogen, CO 2 H, cyano, O(C═O) 0-1 C 1-6 alkyl, NO 2 , trifluoromethoxy, trifluoroethoxy, —O (0-1) (C 1-10 )perfluoroalkyl, C 0-10 alkylaminocarbonylamino, C 0-10 alkyloxycarbonylaminoC 0-10 alkyl, C 0-10 alkylcarbonylaminoC 0-10 alkyl, C 0-10 alkylaminosulfonylaminoC 0-10 alkyl, C 0-10 alkylsulfonylaminoC 0-10 alkyl, C 0-10 alkylsulfonyl, C 0-10 alkylaminosulfonyl, C 0-10 alkylaminocarbonyl, —(C═O)N(C 0-6 alkyl) 2 , —S(C 0-6 alkyl), and NH 2 ;

R a is chosen from hydrogen; —C 1-10 alkyl, —(C 1-6 alkyl)C 3-8 cycloalkyl; and

—(C 1-6 alkyl)phenyl; and

R b , R c , and R d are each independently chosen from hydrogen, —C 1-10 alkyl, —C 3-10 cycloalkyl, aryl, and heterocyclyl, wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted by one or more subtstituents R 10 .

2. A compound of claim 1 wherein X is 0, Y is —CR 4 R 5 and W is —CR 6 R 7 .

3. A compound of claim 1 wherein Y is 0, X is —CR 4 R 5 and W is —CR 6 R 7 .

4. A compound of claim 1 wherein W is 0, X is —CR 4 R 5 and X is —CR 6 R 7 .

5. A compound of claim 1 wherein R 1 is selected from —C 0-10 alkylaryl, and —C 0-10 alkylheterocyclyl.

6. A compound of claim 1 wherein —C 0-10 alkylaryl is —C 1-3 alkylaryl and the aryl moiety is selected from phenyl, napthyl, tetrahydronaphthyl, indanyl, biphenyl and 2,3-dihydroindenyl.

7. A compound of claim 6 wherein the group —C 1-3 alkylaryl is selected from —C 1-3 alkyl phenyl, —C 1-3 alkyl biphenyl and —C 1-3 alkyl 2,3-dihydroindenyl.

8. A compound of claim 1 wherein —C 0-10 alkylheterocyclyl is —C 1-3 alkyl heterocyclyl and the heterocyclyl moiety is selected from azabenzimidazolyl, benzoimidazolyl, benzofuryl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzothiazolyl, benzothienyl, benzoxazolyl, carbazolyl, carbolinyl, chromanyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuryl, isochromanyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazolinyl, isoxazolinyl, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, aziridinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuryl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuryl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydroquinolinyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzo-1,4-dioxinyl, imidazo(2,1-b)(1,3)thiazole, pyrimidinylphenyl, pyridinylphenyl, and benzo-1,3-dioxolyl.

9. A compound of claim 8 , wherein —C 1-3 alkyl heterocyclyl and the heterocyclyl moiety is selected from indolyl, pyridinyl, phenyl, thiazolyl, triazolyl, oxadiazolyl, benzothiazolyl, oxazolyl, benzothienyl, pyrazolyl, pyrazinyl, pyridazinyl, and pyridinyl.

10. A compound of claim 5 wherein R 8 is hydrogen.

11. A compound of claim 1 selected from:

N-{[(1-(1,3-benzothiazol-2-ylmethyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl)glycine;

N-({4-hydroxy-2-oxo-1-[4-(trifluoromethyl)benzyl]-1,2,5, 7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(4-hydroxy-2-oxo-1-{[6-(trifluoromethyl)pyridine-3-yl]methyl}-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-(pyridazin-3-ylmethyl)-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl}glycine;

N-({4-hydroxy-2-oxo-1-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({4-hydroxy-2-oxo-1-[4-(trifluoromethoxy)benzyl]-1,2,5, 7-tetrahydrofuro[3,4-b]pyridin-3-y1}carbonyl)glycine;

N-({4-hydroxy-1-[(5-methylpyrazin-2-yl)methyl-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-{[4-hydroxy-1-(4-isopropoxybenzyl)-2-oxo-1,2,5,7-tetrahydrofuro[3 4-b]pyridin-3-yl]carbonyl}glycine;

N-({1-[(6-chloropyridin-3-yl)methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-{[1-(4-bromobenzyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl)glycine;

N-{[1-(2,3-dihydro-1H-inden-2-ylmethyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl}glycine;

N-({1-[(5-chloropyrazin-2-yl)methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({4-hydroxy-5-methyl-2-oxo-1-[4-(trifluoromethyl)benzyl]-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(4-hydroxy-5-methyl-2-oxo-1-{[6-(trifluoromethyl)pyridine-3-yl]methyl}-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-{[1-(4-bromo-2-fluorobenzyl)-4-hydroxy-2-oxo-1,2,5, 7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl}glycine;

N-{[1-(3-chlorobenzyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl}glycine;

N-{[1-(4-difluoromethoxybenzyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl}glycine;

N-({4-hydroxy-2-oxo-1-[3-(1 H-pyrazole-1-yl)benzyl]-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(4-hydroxy-2-oxo-1-{[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]methyl}-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(4-hydroxy-1-{[1-(2-methylphenyl)-1H-pyrazol-3-yl]methyl}-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-({4-hydroxy-1-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(1-{[1-(4-fluorophenyl)-1 H-pyrazol-3-yl]methyl-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-({4-hydroxy-2-oxo-1-[4-(1,3-thiazol-2-yl)benzyl]-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({4-hydroxy-2-oxo-1-[4-(2,2,2-trifluoroethoxy)benzyl]-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-{[(1-(1,3-benzothiazol-2-ylmethyl)-4-hydroxy-7,7-dimethyl-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl)glycine;

N-[(1-{[4-(2,4-dichlorophenyl)-1,3-thiazol-2-yl]methyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(1-{[4-(2-chlorophenyl)-1,3-thiazol-2-yl]methyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-({1-[2′-chlorobiphenyl)methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(1-{[6-(2-chlorophenyl)pyridine-3-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({1-[4′-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2,5, 7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({1-[4′-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,5, 7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(4-hydroxy-2-oxo-1-{[2′-(1H-pyrazol-yl)biphenyl-4-yl]methyl}-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(4-hydroxy-2-oxo-1-{[2′-(trifluoromethyl)biphenyl-4-yl]methyl}1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(4-hydroxy-1-{[2′-(2,2,2-trifluoroethoxy)biphenyl-4-yl]methyl}-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({1-[2′,4′-dichlorobiphenyl-4-yl)methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(4-hydroxy-1-{[2′-(methoxycarbonyl)biphenyl-4-yl]methyl}-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({1-[2′-chloro-4′-fluorobiphenyl-4-yl)methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({1-[2′-chloro-3-fluorobiphenyl-4-yl)methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({1-[2′-chloro-3,4′-difluorobiphenyl-4-yl)methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-{[1-({2′-(diethylamino)carbonyl]-3-fluorobiphenyl-4-yl}methyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-({4-hydroxy-2-oxo-1-[(6-phenylpyridin-3-yl)methyl]1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine;

N-[(1-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(4-hydroxy-1-{[6-(1-methyl1H-pyrazol-4-yl)pyridin-3-yl)methyl}-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(1-{[6-(2,4-difluorophenyl)pyridin-3-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(1-{[6-(2,5-difluorophenyl)pyridin-3-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-({6-[2,2,2-trifluoroethoxy)phenyl]pyridin-3-yl}methyl]1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl}glycine;

N-{[4-hydroxy-2-oxo-1-({6-[2-(trifluoromethyl)phenyl]pyridin-3-yl}methyl)-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl}glycine;

N-{[4-hydroxy-2-oxo-1-({6-[2-(trifluoromethoxy)phenyl]pyridin-3-yl}methyl)-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl]carbonyl}glycine;

N-[(1-{[6-(2-fluorophenyl)pyridin-3-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(1-{[6-(2-chloro-4-fluorophenyl)pyridin-3-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(1-{[5-(2,4-difluorophenyl)pyrazin-2-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(1-{[5-(3,4-difluorophenyl)pyrazin-2-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(1-{[5-(2-chlorophenyl)pyrazin-2-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine;

N-[(1-{[5-(2-trifluoromethoxyphenyl)pyrazin-2-yl]methyl}-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl)carbonyl]glycine, and pharmaceutically acceptable salts thereof.

12. A pharmaceutical composition comprising a compound of claim 1 and pharmaceutically acceptable carrier.

13. A method of enhancing endogenous production of erythropoietin in a mammal which comprises administering to the mammal an amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof that is effective for enhancing endogenous production of erythropoietin.

14. A method for treatment of anemia in a mammal which comprises administering to the mammal an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (1)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →